BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

Assembly Biosciences (ASMB)Assembly BiosciencesConference / presentation

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.

Open original release

Related news

ASMBAssembly Biosciences2025-10-10 12:00 EST

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

ASMBAssembly Biosciences2026-04-09 12:00 EST

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

ABUSArbutus2025-10-07 12:01 EST

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

AVIRAtea2025-11-19 12:00 EST

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

SPROSpero Therapeutics2024-10-16 16:05 EST

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

ABUSArbutus2025-04-23 06:01 EST

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

View all latest news

Assembly Biosciences

Assembly Biosciences is a biotechnology company focused on antiviral disease biology and microbiome-related discovery. Its story is built around trying to translate targeted biology into therapies for difficult infectious diseases.

Recent company news

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-05-26 20:05 EST

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

ASMBAssembly Biosciences2026-05-13 06:00 EST

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Stock data

Close
25.91 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States